SCHEMBL180433

SCHEMBL180433

CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)s1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RARB P10826 15/20 0.64
RARG P13631 14/20 0.64
RARA P10276 13/20 0.64
CYP3A4 P08684 3/20 0.64
KMT2A Q03164 1/20 0.64
CYP26A1 O43174 2/20 0.51
RXRA P19793 2/20 0.39
CRABP2 P29373 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
ERN1 O75460 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30374339 1.00 RARB (0.64) RARBRARGRARACYP3A4KMT2A
SCHEMBL9453305 0.87 RARB (0.51) RARBRARGRARACYP3A4KMT2A
SCHEMBL6669229 0.86 RARB (0.61) RARBRARGRARACYP3A4KMT2A
SCHEMBL444860 0.85 RARB (0.78) RARBRARGRARACYP3A4KMT2A
SCHEMBL6668880 0.82 RARB (0.54) RARBRARGRARACYP3A4KMT2A
SCHEMBL19342893 0.82 RARA (0.65) RARBRARGRARACYP3A4KMT2A
SCHEMBL9817871 0.82 RARA (0.71) RARBRARGRARACYP3A4KMT2A
SCHEMBL19342953 0.82 RARA (0.65) RARBRARGRARACYP3A4KMT2A
SCHEMBL9142994 0.82 RARA (0.46) RARBRARGRARACYP3A4KMT2A
SCHEMBL19342898 0.81 RARA (0.64) RARBRARGRARACYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018218242-A1 METHODS AND COMPOSITIONS FOR COMBINATION THERAPY EPICENTRX, INC. (US) 2018-11-29 WO claimed
US-9107844-B2 Topical skin treating compositions STIEFEL LABORATORIES INC. (US) 2015-08-18 US claimed
US-20120259014-A1 TOPICAL RETNOID SOLUTIONS RANBAXY LABORATORIES LIMITED (IN) 2012-10-11 US claimed
EP-2432453-A2 TOPICAL RETINOID SOLUTIONS Ranbaxy Laboratories Limited (IN) 2012-03-28 EP claimed
WO-2010134048-A2 TOPICAL RETINOID SOLUTIONS RANBAXY LABORATORIES LIMITED (IN) 2010-11-25 WO claimed
US-20090226380-A1 Topical Skin Treating Compositions STIEFEL LABORATORIES INC. 2009-09-10 US claimed
EP-1898896-A2 TOPICAL SKIN TREATING COMPOSITIONS STIEFEL LABORATORIES, INC. (US) 2008-03-19 EP claimed
WO-2007002831-A2 TOPICAL SKIN TREATING COMPOSTIONS STIEFEL LABORATORIES, INC. (US) 2007-01-04 WO claimed
US-20070003585-A1 Topical skin treating compositions STIEFEL LABORATORIES, INC. (US) 2007-01-04 US claimed
EP-0785782-B1 USE OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY ALLERGAN INC (US) 2004-09-08 EP claimed
EP-0785782-A1 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY Allergan (US) 1997-07-30 EP claimed
US-5602130-A ORNITHINE DECARBOXYLASE ENZYME INHIBITOR TREATING SKIN DISORDER, INHIBITING CELL HYPERPROLIFERATION ALLERGAN 1997-02-11 US claimed
WO-1996011686-A1 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY ALLERGAN (US) 1996-04-25 WO claimed
US-5348972-A In treatment of skin disorders such as acne and psoriasis ALLERGAN, INC. (US) 1994-09-20 US claimed
US-20260014134-A1 COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY DAVIS ADRIAN (GB) 2026-01-15 US disclosed
EP-4167959-B1 COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY LIMEWAY PHARMA DESIGN LTD (GB) 2024-08-28 EP disclosed
US-20230210835-A1 COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY LIMEWAY PHARMA DESIGN LTD (GB) 2023-07-06 US disclosed
US-5348972-A In treatment of skin disorders such as acne and psoriasis ALLERGAN, INC. (US) 1994-09-20 US disclosed
US-5234926-A Skin disorders ALLERGAN, INC. (US) 1993-08-10 US disclosed
US-5089509-A Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity ALLERGAN, INC. (US) 1992-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014134-A1 COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY LRBA, DNER, KRT18 RARB 189/4885RARG 535/4885RARA 262/4885
US-20230210835-A1 COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY CUTA, SGMS1, CERS2 RARB 173/4885RARG 270/4885RARA 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.